Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Non-Current Deferred Tax Liability (2017 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Non-Current Deferred Tax Liability for 9 consecutive years, with $30.1 million as the latest value for Q3 2025.

  • On a quarterly basis, Non-Current Deferred Tax Liability changed 0.0% to $30.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was $30.1 million, a 0.0% change, with the full-year FY2024 number at $30.1 million, changed 0.0% from a year prior.
  • Non-Current Deferred Tax Liability was $30.1 million for Q3 2025 at Ultragenyx Pharmaceutical, roughly flat from $30.1 million in the prior quarter.
  • In the past five years, Non-Current Deferred Tax Liability ranged from a high of $33.3 million in Q1 2021 to a low of $30.1 million in Q4 2023.
  • A 5-year average of $31.6 million and a median of $31.7 million in 2022 define the central range for Non-Current Deferred Tax Liability.
  • Peak YoY movement for Non-Current Deferred Tax Liability: changed 0.0% in 2021, then dropped 5.08% in 2023.
  • Ultragenyx Pharmaceutical's Non-Current Deferred Tax Liability stood at $33.3 million in 2021, then dropped by 4.92% to $31.7 million in 2022, then decreased by 5.08% to $30.1 million in 2023, then changed by 0.0% to $30.1 million in 2024, then changed by 0.0% to $30.1 million in 2025.
  • Per Business Quant, the three most recent readings for RARE's Non-Current Deferred Tax Liability are $30.1 million (Q3 2025), $30.1 million (Q2 2025), and $30.1 million (Q1 2025).